Mucosal Healing at 14 Weeks Predicts better Outcome in Low-dose Infliximab Treatment for Chinese Patients with Active Intestinal Behcet's Disease.

Abstract

AIMS:

To compare the efficacy and the safety of low-dose (3.5 mg/kg) or standard-dose (5 mg/kg) of infliximab (IFX) for induction and maintenance treatment in Chinese patients with intestinal Behcet's disease (BD), and to identify potential predictors to corticosteroid-free clinical remission at week 30.

METHODS:

A prospective trial was conducted in 20 patients with moderate-to-severe active intestinal BD, followed up for 30 weeks. Ileocolonoscopic examinations were done at baseline and week 14. A logistic regression model was used to assess the predictors of corticosteroid-free remission at week 30.

RESULTS:

As the primary end point, steroid-free remission at week 30 was observed in 40% and 60% of patients who received low and standard doses of IFX, respectively (P>0.371). As the secondary end point, the mucosal healing (MH) rates at week 14 were found to be 60% for both low and standard doses of IFX. The clinical response rates at week 14 and 30 were also similar in both groups. Only MH at week 14 predicted steroid-free clinical remission at week 30.

CONCLUSIONS:

Low-dose of IFX is effective and safe for induction and maintenance therapy in patients with active intestinal BD. MH at week 14 predicted clinical remission at week 30.

• Authors: Jun Zou, Da-Nian Ji, Yan Shen, Jian-Long Guan, Song-Bai Zheng
• Journal: Annals of clinical and laboratory science (Ann Clin Lab Sci) Vol. 47 Issue 2 Pg. 171-177 (Mar 2017) ISSN: 1550-8080 [Electronic] United States
• PMID: 28442519 (Publication Type: Clinical Trial, Journal Article)
• Copyright: © 2017 by the Association of Clinical Scientists, Inc.

Chemical References

• Infliximab

Topics

• Adolescent
• Adult
• Aged
• Asian People
• Behcet Syndrome (drug therapy, pathology)
• Demography
• Dose-Response Relationship, Drug
• Endpoint Determination
• Female
• Humans
• Infliximab (administration & dosage, adverse effects, therapeutic use)
• Intestinal Mucosa (pathology)
• Male
• Middle Aged
• Remission Induction
• Treatment Outcome
• Wound Healing
• Young Adult